文献速递眼底病与葡萄膜炎

全视网膜光凝或雷珠单抗治疗眼中增殖性糖尿病视网膜病变恶化的相关因素

Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
PubMed 文献 · Ophthalmology · 2017-02-01

这项随机临床试验纳入305名成人增殖性糖尿病视网膜病变(PDR)患者的394只研究眼,比较全视网膜光凝(PRP)与玻璃体内注射雷珠单抗(0.5 mg/0.05 ml)后PDR恶化情况。2年时PDR恶化累积概率PRP组42% vs 雷珠单抗组34%(HR 1.33,99%CI 0.90-1.98,P=0.063)。基线糖尿病视网膜病变严重程度更高者恶化风险增加(高风险PDR或更差64% vs 中度PDR或更好23%;HR 3.97,99%CI 2.48-6.36,P<0.001)。

要点

  • 2年PDR恶化累积概率PRP组42% vs 雷珠单抗组34%(HR 1.33,99%CI 0.90-1.98,P=0.063),未达统计学显著。
  • 基线糖尿病视网膜病变严重程度更高者恶化风险增加(高风险PDR或更差64% vs 中度PDR或更好23%;HR 3.97,99%CI 2.48-6.36,P<0.001)。
  • 在无视力损害性中心凹受累DME的眼中,PRP组PDR恶化率高于雷珠单抗组(45% vs 31%;HR 1.62,99%CI 1.01-2.60,P=0.008)。

核心结论

  • 在有PDR的眼中,雷珠单抗相比PRP导致更少的PDR恶化,尤其是在不需要因中心凹受累DME而接受雷珠单抗的眼。
  • 尽管抗血管内皮生长因子治疗比PRP需要更频繁的访视频率,这些发现提供了额外证据支持雷珠单抗作为PDR的PRP替代疗法,至少通过2年。

研究设计与样本

  • 随机临床试验,在美国55个中心进行。
  • 纳入305名成人PDR患者的394只研究眼,视力20/320或更好,且无PRP史。
  • 干预为全视网膜光凝或玻璃体内注射雷珠单抗(0.5 mg/0.05 ml)。

主要发现

  • 2年时PDR恶化累积概率PRP组42% vs 雷珠单抗组34%(HR 1.33;99%CI 0.90-1.98;P=0.063)。
  • 基线糖尿病视网膜病变严重程度更高(早期治疗糖尿病视网膜病变研究量表)与PDR恶化风险增加相关,无论治疗组(高风险PDR或更差64% vs 中度PDR或更好23%;HR 3.97;99%CI 2.48-6.36;P<0.001)。
  • 在PRP组中,接受模式扫描PRP的眼相比传统单点PRP的眼PDR恶化风险更高(60% vs 39%;HR 2.04;99%CI 1.02-4.08;P=0.008),无论放置的点数或完成初始PRP的次数。
  • 在基线无视力损害性(视力20/32或更差)中心凹受累DME的眼中,PRP组PDR恶化率高于雷珠单抗组(45% vs 31%;HR 1.62;99%CI 1.01-2.60;P=0.008)。

关键数值与推荐

  • PDR恶化复合结局定义为首次发生玻璃体出血、视网膜脱离、前节新生血管或新生血管性青光眼。
  • 基线有视力损害性(视力20/32或更差)中心凹受累DME的眼在两组中均需接受雷珠单抗治疗中心凹受累DME。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为,这些发现提供了额外证据支持雷珠单抗作为PDR的PRP替代疗法,至少通过2年。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare rates and identify predictive factors for events that represent worsening of proliferative diabetic retinopathy (PDR) in eyes treated with panretinal photocoagulation (PRP) or ranibizumab. DESIGN: Randomized clinical trial (55 United States sites). PARTICIPANTS: Three hundred ninety-four study eyes from 305 adults with PDR, visual acuity (VA) 20/320 or better, and no history of PRP. INTERVENTION: Panretinal photocoagulation or intravitreous ranibizumab injections (0.5 mg/0.05 ml). MAIN OUTCOME MEASURES: Time from randomization to a composite PDR-worsening outcome defined as the first occurrence of vitreous hemorrhage, retinal detachment, anterior segment neovascularization, or neovascular glaucoma. RESULTS: Through 2 years, the cumulative probability of worsening PDR was 42% (PRP) versus 34% (ranibizumab; hazard ratio [HR], 1.33; 99% confidence interval [CI], 0.90 to 1.98; P = 0.063). Worse baseline levels of diabetic retinopathy severity (Early Treatment Diabetic Retinopathy Study scale) were associated with increased risk of worsening PDR, regardless of treatment group (64% [high-risk PDR or worse] vs. 23% [moderate PDR or better]; HR, 3.97; 99% CI, 2.48 to 6.36; P < 0.001). In the PRP group, eyes receiving pattern scan versus conventional single-spot PRP also were at higher risk for worsening PDR (60% vs. 39%; HR, 2.04; 99% CI, 1.02 to 4.08; P = 0.008), regardless of the number of spots placed or the number of sittings to complete the initial PRP. Eyes in both groups with vision-impairing (VA 20/32 or worse) center-involved diabetic macular edema (DME) at baseline were required to receive ranibizumab for center-involved DME. Therefore the composite outcome was compared by treatment in the subgroup of eyes that did not have vision-impairing center-involved DME at baseline. For these eyes, the rate of PDR-worsening was greater with PRP than ranibizumab (45% vs. 31%; HR, 1.62; 99% CI, 1.01 to 2.60; P = 0.008). CONCLUSIONS: In eyes with PDR, ranibizumab resulted in less PDR worsening compared with PRP, especially in eyes not required to receive ranibizumab for center-involved DME. Although anti-vascular endothelial growth factor therapy requires a more frequent visit schedule than PRP, these findings provide additional evidence supporting the use of ranibizumab as an alternative therapy to PRP for PDR, at least through 2 years.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Bressler SB, Beaulieu WT, Glassman AR, et al. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab. Ophthalmology. 2017. PMID: 28161147. doi:10.1016/j.ophtha.2016.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。